Bristol Myers Squibb (CELG-RI) Change in Taxes (2009 - 2026)
Bristol Myers Squibb (CELG-RI) reported Change in Taxes of $187.0 million for Q1 2026, up 246.3% year-over-year from $54.0 million in Q1 2025, and up 157.72% quarter-over-quarter from -$324.0 million in Q4 2025.
Bristol Myers Squibb (CELG-RI) Change in Taxes (2009 - 2026) Analysis & Trends
Bristol Myers Squibb (CELG-RI) has 18 years of Change in Taxes data on file, last reported at $187.0 million in Q1 2026.
- Change in Taxes for Q1 2026 came in at $187.0 million, up 246.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $129.0 million (up 106.1% YoY), and the FY2025 annual result was -$4.0 million, up 99.68% from the prior year.
- Change in Taxes rose to $187.0 million in Q1 2026 per CELG-RI's latest filing, from -$324.0 million in the prior quarter.
- Over five years, Change in Taxes peaked at $1.0 billion in Q4 2023 and troughed at -$2.1 billion in Q2 2023.
- A 5-year average of -$182.5 million and a median of $54.0 million in 2025 frame the typical range for Change in Taxes.
- The sharpest annual moves came in 2023 and 2025: Change in Taxes tumbled 786.67% in 2023, then surged 354.89% in 2025.
- A 5-year view of Change in Taxes shows it stood at -$1.1 billion in 2022, then soared by 193.8% to $1.0 billion in 2023, then sank by 88.41% to $121.0 million in 2024, then tumbled by 367.77% to -$324.0 million in 2025, then soared by 157.72% to $187.0 million in 2026.
- Business Quant data shows CELG-RI's Change in Taxes at $187.0 million in Q1 2026, -$324.0 million in Q4 2025, and $887.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | 411.19 Mn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | - |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | - |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -81.00 Mn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | - |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 71.00 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | -29.00 Mn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | - |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 187.00 Mn |
| 10 | Bristol Myers Squibb | - | - | 8.07 Bn | 187.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 187.00 Mn |
| Mar 31, 2026 | 187.00 Mn |
| Dec 31, 2025 | -324.00 Mn |
| Dec 31, 2025 | -324.00 Mn |
| Sep 30, 2025 | 887.00 Mn |
| Sep 30, 2025 | 887.00 Mn |
| Jun 30, 2025 | -621.00 Mn |
| Jun 30, 2025 | -621.00 Mn |
| Mar 31, 2025 | 54.00 Mn |
| Mar 31, 2025 | 54.00 Mn |
| Dec 31, 2024 | 121.00 Mn |
| Dec 31, 2024 | 121.00 Mn |
| Sep 30, 2024 | -348.00 Mn |
| Sep 30, 2024 | -348.00 Mn |
| Jun 30, 2024 | -1.94 Bn |
| Jun 30, 2024 | -1.94 Bn |
| Mar 31, 2024 | 910.00 Mn |
| Mar 31, 2024 | 910.00 Mn |
| Dec 31, 2023 | 1.04 Bn |
| Dec 31, 2023 | 1.04 Bn |